<?xml version="1.0" encoding="UTF-8"?>
<ref id="B15-biomedicines-08-00060">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Weber</surname>
    <given-names>J.S.</given-names>
   </name>
   <name>
    <surname>Dâ€™Angelo</surname>
    <given-names>S.P.</given-names>
   </name>
   <name>
    <surname>Minor</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Hodi</surname>
    <given-names>F.S.</given-names>
   </name>
   <name>
    <surname>Gutzmer</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Neyns</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Hoeller</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Khushalani</surname>
    <given-names>N.I.</given-names>
   </name>
   <name>
    <surname>Miller</surname>
    <given-names>W.H.</given-names>
   </name>
   <name>
    <surname>Lao</surname>
    <given-names>C.D.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial</article-title>
  <source>Lancet Oncol.</source>
  <year>2015</year>
  <volume>16</volume>
  <fpage>375</fpage>
  <lpage>384</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(15)70076-8</pub-id>
  <pub-id pub-id-type="pmid">25795410</pub-id>
 </element-citation>
</ref>
